Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis

Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Key Stats

• Today's Range: $5.53 to $5.76
• 50-Day Range: $5.39 to $8.37
• 52-Week Range: $5.21 to $19.71
• Volume: 723,043 shs
• Average Volume: 992,463 shs
• Market Capitalization: $387.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Moderate Buy

Phathom Pharmaceuticals Stock Analysis - MarketRank™

Phathom Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 500th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Phathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Phathom Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.78) to ($4.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phathom Pharmaceuticals is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phathom Pharmaceuticals is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.40% of the outstanding shares of Phathom Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently increased by 3.03%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phathom Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phathom Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

21.40% of the outstanding shares of Phathom Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Phathom Pharmaceuticals has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Phathom Pharmaceuticals has recently increased by 3.03%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.05

News Sentiment

Phathom Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for PHAT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Phathom Pharmaceuticals insiders have sold 142.67% more of their company's stock than they have bought. Specifically, they have bought $99,125.00 in company stock and sold $240,551.00 in company stock.

Percentage Held by Insiders

24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHAT Stock Analysis - Frequently Asked Questions

How have PHAT shares performed this year?

Phathom Pharmaceuticals' stock was trading at $8.12 at the beginning of 2025. Since then, PHAT shares have decreased by 30.2% and is now trading at $5.67.
View the best growth stocks for 2025 here.

How were Phathom Pharmaceuticals' earnings last quarter?

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.57) by $0.25. The firm had revenue of $16.35 million for the quarter, compared to the consensus estimate of $12.54 million.

When did Phathom Pharmaceuticals IPO?

Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Phathom Pharmaceuticals' major shareholders?

Top institutional investors of Phathom Pharmaceuticals include Jennison Associates LLC (10.33%), Invesco Ltd. (5.37%), Vanguard Group Inc. (4.07%) and Ensign Peak Advisors Inc (3.70%). Insiders that own company stock include Pharmaceutical Co Ltd Takeda, Terrie Curran, Azmi Nabulsi, Frank Karbe and Asit Parikh.
View institutional ownership trends.

How do I buy shares of Phathom Pharmaceuticals?

Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Phathom Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phathom Pharmaceuticals investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHAT
• CUSIP: N/A
• CIK: 1783183
• Web: www.phathompharma.com
• Phone: 877-742-8466
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $28.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +305.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-201,590,000.00
• Net Margins: -1,292.14%
• Pretax Margin: -1,292.14%
• Return on Equity: N/A
• Return on Assets: -79.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.73
• Quick Ratio: 5.68

Sales & Book Value

• Annual Sales: $680,000.00
• Price / Sales: 570.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.27) per share
• Price / Book: -4.46

Miscellaneous

• Outstanding Shares: 68,380,000
• Free Float: 51,898,000
• Market Cap: $387.71 million
• Optionable: Optionable
• Beta: 0.54